|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
139,229 |
182,993 |
316,353 |
594,697 |
Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$56,737,885 |
Total People Sold |
5 |
5 |
6 |
7 |
Total Sell Transactions |
11 |
15 |
24 |
53 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Grey Michael G |
Director |
|
2013-03-06 |
4 |
S |
$60.61 |
$909,135 |
D/D |
(15,000) |
19,650 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2013-03-04 |
4 |
S |
$60.18 |
$240,724 |
D/D |
(4,000) |
46,200 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2013-03-04 |
4 |
OE |
$17.86 |
$71,440 |
D/D |
4,000 |
50,200 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-03-04 |
4 |
AS |
$60.00 |
$240,000 |
D/D |
(4,000) |
10,570 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-03-04 |
4 |
OE |
$21.51 |
$86,040 |
D/D |
4,000 |
14,570 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-03-04 |
4 |
AS |
$60.00 |
$300,000 |
I/I |
(5,000) |
13,545 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-03-04 |
4 |
OE |
$12.99 |
$64,950 |
I/I |
5,000 |
23,545 |
|
- |
|
Grey Michael G |
Director |
|
2013-03-03 |
4 |
OE |
$14.39 |
$215,850 |
D/D |
15,000 |
34,650 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-03-01 |
4 |
AS |
$59.14 |
$59,140 |
D/D |
(1,000) |
119,401 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2013-03-01 |
4 |
S |
$59.81 |
$120,510 |
D/D |
(2,015) |
13,279 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2013-03-01 |
4 |
S |
$59.74 |
$300,067 |
D/D |
(5,023) |
15,294 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2013-03-01 |
4 |
OE |
$14.39 |
$91,464 |
D/D |
5,023 |
20,317 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2013-03-01 |
4 |
D |
$59.61 |
$113,736 |
D/D |
(1,908) |
44,589 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-02-28 |
4 |
AS |
$58.00 |
$290,000 |
I/I |
(5,000) |
18,545 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-02-28 |
4 |
OE |
$12.99 |
$64,950 |
I/I |
5,000 |
18,545 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2013-02-27 |
4 |
S |
$56.90 |
$455,186 |
D/D |
(8,000) |
46,200 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2013-02-27 |
4 |
OE |
$14.39 |
$125,884 |
D/D |
8,000 |
54,200 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-02-27 |
4 |
S |
$56.46 |
$84,683 |
D/D |
(1,500) |
120,401 |
|
- |
|
Lewis Alan |
Director |
|
2013-02-27 |
4 |
S |
$56.57 |
$1,272,762 |
D/D |
(22,500) |
15,900 |
|
- |
|
Lewis Alan |
Director |
|
2013-02-27 |
4 |
OE |
$14.39 |
$558,675 |
D/D |
22,500 |
38,400 |
|
- |
|
Lapalme Pierre |
Director |
|
2013-02-26 |
4 |
S |
$55.34 |
$1,654,798 |
D/D |
(29,900) |
24,650 |
|
- |
|
Lapalme Pierre |
Director |
|
2013-02-26 |
4 |
OE |
$8.47 |
$306,853 |
D/D |
29,900 |
54,550 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2013-02-22 |
4 |
AS |
$55.00 |
$171,344 |
D/D |
(3,103) |
23,245 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2013-02-22 |
4 |
OE |
$14.39 |
$72,412 |
D/D |
3,103 |
26,348 |
|
- |
|
Meier Richard A |
Director |
|
2013-02-19 |
4 |
AS |
$57.50 |
$287,500 |
D/D |
(5,000) |
18,650 |
|
- |
|
1279 Records found
|
|
Page 12 of 52 |
|
|